Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention relates to avidin-type molecules having 2,4,6-trinitrophenyl or lactosyl groups or being complexed with an antibody specific to the avidin-type molecule, which shifts the biodistribution pattern in tissues and organs to the liver, where these molecules accumulate at high levels over several days. These modified avidin-type molecules provide a means for delivery of diagnostic and therapeutic agents, including radionuclides to the liver and cells of the reticuloendothelial system (RES) for diagnosing and treating hepatic disorders and disorders of the RES.

Abstract: The present invention relates to the treatment of multiple sclerosis by ingestion or inhalation of copolymet-1 and pharmaceutical compositions useful for such treatment.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: Pharmaceutical compositions comprising as active ingredient a synthetic random copolymer of average molecular weight of about 4,000-12,000, preferably 6,000-8,000, said copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-4.4 parts of Lys to 4.0-6.0 parts of Ala to 1.0 parts of Tyr (herein GLAT copolymers), can be used in a method for prevention and treatment of graft-versus-host disease in patients in the course of bone marrow and organ transplantation.

Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Abstract: The invention relates to a number of synthetic polypeptides which correspond to a part of the sequences of the Shiga B peptide chain. More specifically, the invention relates to polypeptides corresponding to the residues 5 to 18, 7 to 26, 13 to 26, and 19 to 29 of said B chain. The invention further relates to the conjugates of each of these with a suitable carrier and to polymers of each or these obtained by polymerization with a suitable polymerization agent: these can be used as effective vaccines which afford protection against Shiga toxin. Anti-peptide anti-sera are effective in neutralizing to a large extent the biological activity of Shiga toxin.

Abstract: A method is provided for detecting and measuring acetaldehyde-protein condensates. An antibody is produced to an antigen, the antibody being cross-reactive with acetaldehyde-protein condensates, these condensates including protein moieties corresponding to or different from the protein moiety of the antigen. Detection and measurement of acetaldehyde-protein condensates may be performed by reacting the antibody with the acetaldehyde-protein condensate to form a complex and measuring the complex.

Abstract: A synthetic vaccine against cholera and against heat-labile toxin of E. coli comprising a conjugate of a high-molecular weight carrier with a synthetic polypeptide corresponding to part of the sequence of Subunit B of natural cholera toxin. The sequences of choice are those corresponding to sequences 45 to 64, 50 to 64 and 8 to 20 of Subunit B, or slightly modified sequences, similar to the above.

Abstract: There is provided a synthetic vaccine against influenza virus infections consisting of a synthetic peptide corresponding to a relevant antigenic fragment of the virus, which fragment is attached to a suitable carrier, such as a macromolecule. Effective vaccinations against a plurality of strains can be obtained when the antigenic fragment is one common to such strains. Such synthetic vaccines are produced by synthesizing peptides corresponding to such relevant antigenic fragments and coupling same to a suitable carrier, such as a macromolecule. There is also provided a process for the vaccination of mammals against influenza which comprises applying to said mammals an effective quantity of a vaccine according to the invention.

Abstract: Novel pharmaceutically active compositions of matter comprise in combination a low-molecular-weight anti-cancer drug chemically linked to antibodies selective or specific to tumor antigens. The preferred linkage is via covalent bonds, whether directly or via a linking agent. A method of treatment of mammals afflicted with malignant growth comprises administering a pharmaceutical composition of matter defined above.

Abstract: Chemotherapeutic agents comprising an antigen binding dimer derived from an immunoglobulin covalently bound to a drug are disclosed. The dimer and drug are bound, while preserving both the antibody activity of the dimer and the pharmacological activity of the drug.

Abstract: A novel synthetic peptide corresponding to the eleven amino acid residues of the NH.sub.2 -terminal portion in the sequence of carcinoembrionic antigen (CEA) has been synthesized and this was attached by means of a water-soluble carbodiimide reagent to multichain poly(DL)-alanine as well as to bovine serum albumin. The resulting macromolecular conjugates provoked rabbit anti- CEA(1-11) peptide antibodies and a novel assay was developed for ascertaining the presence of adenocarcinomas of the digestive tract, pancreas and breast, based on said novel compositions of matter.